Related Experiment Video

Updated: Feb 28, 2026

Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors
04:36

Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors

Published on: October 17, 2025

1.0K

Intracranial and Systemic Response to Alectinib in a Patient with RET-KIF5B Oncogenic Fusion

Vamsidhar Velcheti1, Manmeet Ahluwalia1

  • 1Department of Solid Tumor Oncology, Cleveland Clinic, Cleveland, Ohio.

Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|June 21, 2017
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Oncogenic Gene Fusion Detection Using Anchored Multiplex Polymerase Chain Reaction Followed by Next Generation Sequencing
09:49

Oncogenic Gene Fusion Detection Using Anchored Multiplex Polymerase Chain Reaction Followed by Next Generation Sequencing

Published on: July 5, 2019

10.1K
Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

18.7K

Related Experiment Videos

Last Updated: Feb 28, 2026

Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors
04:36

Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors

Published on: October 17, 2025

1.0K
Oncogenic Gene Fusion Detection Using Anchored Multiplex Polymerase Chain Reaction Followed by Next Generation Sequencing
09:49

Oncogenic Gene Fusion Detection Using Anchored Multiplex Polymerase Chain Reaction Followed by Next Generation Sequencing

Published on: July 5, 2019

10.1K
Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

18.7K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Intracellular Signaling Affects Focal Adhesions01:17

Intracellular Signaling Affects Focal Adhesions

3.7K
Integrins act both as extracellular input receivers and as intracellular processing activators. As their name suggests, integrins are entirely integrated into the membrane structure. Their hydrophobic membrane-spanning regions interact with the phospholipid bilayer's hydrophobic region. These membrane receptors provide extracellular attachment sites for effectors like hormones and growth factors. They activate intracellular response cascades when their effectors are bound and active.
Some...
3.7K

Articles linked to this work by shared authors, journal, and citation graph.

A shared injury-homeostasis gradient in the human CSF proteome across neurological disease.

Research square·2026

Real-world effectiveness of pembrolizumab for first-line treatment of metastatic non-small-cell lung cancer: a decade of evidence and experience.

Future oncology (London, England)·2026

Phase III Study of Niraparib Plus Pembrolizumab as Maintenance Therapy for Advanced or Metastatic NSCLC (ZEAL-1L).

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2026

Current Roles of Neoadjuvant and Perioperative Immunotherapy in Non-Small Cell Lung Cancer.

JCO oncology practice·2026

Phase 2 study of regorafenib in patients with progressive glioblastoma after failure of bevacizumab.

Neuro-oncology advances·2026

Understanding the Promise and Challenges of Tumor-Agnostic Therapy: Could One Size Really Fit All?

Cancers·2026

Advances in Pathology: Journal of Thoracic Oncology 20th Anniversary Series.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2026

Brief Report: Validation of the Sybil Lung Cancer Risk Prediction Model in a Predominantly Black Screening Cohort.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2026

Efficacy and safety of HER2 directed therapies for advanced HER2-mutant non-small-cell lung cancer - a systematic review and meta-analysis.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2026

Gene-Specific Analysis of Clonal Hematopoiesis Identifies the Association between ASXL1 and Lung Cancer Risk.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2026

Grade 3 Lung Carcinoids/NETs: The IASLC Pathology Committee Study with Proposal of a New Diagnostic Category.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2026

Long-Term Benefit With First-Line Osimertinib Monotherapy in EGFR-Mutated Advanced NSCLC in the Era of Intensified First-Line Therapy.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2026

Case Report: Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder: Diagnostic Challenges and Transition From B-Cell Depletion Therapy to Ravulizumab.

Clinical case reports·2026

Eculizumab in rapidly progressive glomerulonephritis: a case-series report.

Frontiers in immunology·2026

Flurbiprofen for Inflammatory Bowel Disease: A Review of Colon-Targeted Formulations.

Recent advances in drug delivery and formulation·2026

Optimal Transfusion Thresholds in Patients with Acute Brain Injury: A Bayesian Network Meta-analysis of Randomized Controlled Trials.

Neurocritical care·2026

Heart-specific T cell responses: from antigens to disease mechanisms.

Nature reviews. Cardiology·2026

Perioperative immune-based treatment for cisplatin-eligible muscle-invasive bladder cancer: a meta-analysis of randomized controlled trials.

Critical reviews in oncology/hematology·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us